We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
S-Oxybutynin.
- Abstract
Adis Comments Sepracor is developing S-oxybutynin as a potential treatment for urinary incontinence with fewer anticholinergic adverse events than racemic oxybutynin. Sepracor announced in June 2000 that it had completed a 900-patient phase II trial in the USA. Sepracor stated that the trial results indicated that S-oxybutynin (three times daily) was well tolerated and significantly improved both urinary frequency and urinary incontinence. Sepracor is developing S-oxybutynin as a once-daily, sustained-release product. An initial study in healthy volunteers showed that the target pharmacokinetic profile determined in the phase II trial (of standard S-oxybutynin) was achieved with the new formulation. In June 2001, Sepracor announced that it had initiated a 12-week phase III trial of sustained-release S-oxybutynin in the USA. The study will enrol approximately 850 patients at 70 sites. Sepracor intends to conduct two more phase III trials of S-oxybutynin. Sepracor has been granted a patent for S-oxybutynin in the USA.
- Subjects
URINARY incontinence treatment; CLINICAL trials; SEPRACOR Inc.
- Publication
Drugs in R&D, 2002, Vol 3, Issue 2, p84
- ISSN
1174-5886
- Publication type
Article
- DOI
10.2165/00126839-200203020-00003